Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Juvensis Therapeutics is a China-based biotechnology company focused on developing innovative therapies for aging-related diseases and metabolic disorders. The company leverages its proprietary platform to regulate NAD+ metabolism, aiming to restore cellular health and slow the progression of chronic conditions. Their research primarily targets the Sirtuin pathway and NAD+ biosynthesis to address indications in ophthalmology, neurology, and metabolic health. Juvensis is currently in the pre-clinical stage, advancing a pipeline of small molecule and peptide-based candidates designed to improve healthy lifespan.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Juvensis Therapeutics Biopharmaceutical Technology.